5 news items
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
FENC
14 May 24
/BI137d97d6710341398d6f17d0433dc5b8 To access the conference call, please register using
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
FENC
7 May 24
/BI137d97d6710341398d6f17d0433dc5b8 To access the conference call, please register using
Reported Sunday, Fennec Pharmaceuticals And Norgine Inked An Exclusive Licensing Agreement To Commercialize PEDMARQSI In Europe, Australia, And New Zealand
FENC
18 Mar 24
., Australia, and New Zealand who currently do not have access to a therapy to treat this life altering condition
Under the terms of the licensing
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
FENC
17 Mar 24
to patients in Europe, U.K., Australia, and New Zealand who currently do not have access to a therapy to treat this life altering condition
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
FENC
29 Feb 24
, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent
- Prev
- 1
- Next